Retrospective cohort study delineates hormone signaling differences in atypical endometrial hyperplasia, implying therapeutic targets for management.
This study aimed to delineate the molecular profile underlying progesterone resistance in atypical endometrial hyperplasia (AEH), a precancerous condition associated with a high risk of malignant transformation. Using a retrospective cohort of 20 AEH patients who completed a 6-month progestin therapy, we compared protein expression between 10 progesterone-resistant and 10 progesterone-sensitive tissues using immunohistochemistry and Western blot analysis. The results revealed a distinct molecular signature in resistant tissues, characterized by significant upregulation of estrogen signaling components (ERa, pS2, and MUC1) and proliferation markers (SOX7 and Ki-67). Concurrently, the key progesterone receptor signaling elements (PR, FKBP4, FKBP5, and FOSL2) were markedly downregulated. These findings indicate that progesterone resistance is associated with sustained activation of estrogen-driven proliferative pathways coupled with impaired progesterone signaling, leading to unabated cellular growth. The coordinated dysregulation of these hormone-responsive and proliferation-related molecules highlights a fundamental hormonal imbalance and proliferative disruption in progesterone-resistant AEH. This study provides a molecular framework for understanding progesterone resistance and suggests potential targets, such as SOX7, for future therapeutic strategies aimed at restoring hormonal sensitivity and controlling disease progression in conservative fertility-sparing management.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: